The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 10, 2012
Filed:
Oct. 16, 2007
Peter U. Park, Somerville, MA (US);
Laura M. Bartle, Arlington, MA (US);
Anna Skaletskaya, Cambridge, MA (US);
Viktor Golmakher, Newton, MA (US);
Daniel Tavares, Natick, MA (US);
Jutta Deckert, Lexington, MA (US);
Vincent Mikol, Paris, FR;
Veronique Blanc, Paris, FR;
Peter U. Park, Somerville, MA (US);
Laura M. Bartle, Arlington, MA (US);
Anna Skaletskaya, Cambridge, MA (US);
Viktor Golmakher, Newton, MA (US);
Daniel Tavares, Natick, MA (US);
Jutta Deckert, Lexington, MA (US);
Vincent Mikol, Paris, FR;
Veronique Blanc, Paris, FR;
Sanof Aventis, Paris, FR;
Abstract
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.